ERBB4 and breast carcinoma: This wide range of reported over-expression highlights a fundamental challenge of interpreting previous HER4 studies in breast carcinoma, which is the lack of a clinically validated standard anti-HER4 antibody and IHC scoring algorithm[11, 18, 19].